CohBar Nominates CB5138 Analog as Lead Clinical Candidate for Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases
MENLO PARK, Calif., March 16, 2021 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ: CWBR), a clinical…
Month: March 2021
Adaptive Research Appoints Mark Tsuchiyose, MD as Vice President, Clinical Affairs and Therapeutic Head, Gastroenterology, and Dhira Khosla, DO as Vice President, Strategic Clinical Partnerships, Positioning Company to Drive Continued Growth
SAN FRANCISCO, March 16, 2021 (GLOBE NEWSWIRE) — Adaptive Research Inc. (the “Company”), a healthcare…
Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers
Research focused on targeted degradation of MYCN for the potential treatment of neuroblastoma and medulloblastomaProgram…
BrightInsight and AstraZeneca Collaborate to Enhance Disease Management
BrightInsight Accelerates Time to Market for the AstraZeneca AMAZE Disease Management Platform Within a Regulatory-Compliant…
Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide
TORONTO, March 16, 2021 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX…
Advaxis Reports First Quarter Ended January 31, 2021 Financial Results and Provides a Business Update
Continued enrollment in expanded ADXS-503 HOT program in NSCLC to explore potential to enhance and/or…
Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program
SAFEbody technology enables precision masking of antibodies for enhanced safety SAN FRANCISCO and SUZHOU, China,…
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of Atrasentan for Patients with IgA Nephropathy
Phase 2 AFFINITY Trial of Atrasentan for Patients with Glomerular Diseases Also on Track to…
Better Choice Announces Formation of Strategic Advisory Committee to Review Potential Strategic Opportunities
NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) — Better Choice Company (OTCQX: BTTR) (“Better Choice”…
Skye Bioscience’s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment
San Diego, Calif., March 16, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE”…
Nabriva Publishes Clinical Data Analysis Highlighting Benefits of Outpatient Management of Community Acquired Bacterial Pneumonia (CABP) with Oral XENLETA® (lefamulin)
-Post Hoc analysis published in The Journal of Emergency Medicine demonstrates patients with moderate to…
Amolyt Pharma to Present Preliminary Phase 1 Data on AZP-3601 for Hypoparathyroidism and Additional Preclinical Data on AZP-3404 at ENDO 2021
Four abstracts accepted as poster presentations for the Endocrine Society’s Annual Meeting LYON, France and…
Akero Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic…
Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer
New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD’s KEYTRUDA®…
Vaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update
Reported top-line results from Phase 2 SIGNAL study that indicates potential cognitive benefit of pepinemab…
Pliant Therapeutics Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical Partner
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX),…
Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study of Emricasan in Symptomatic COVID-19 Patients
Topline Results Expected in the Second Quarter of 2021 SAN DIEGO, March 16, 2021 (GLOBE…
Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy Candidates
Programs receiving funding include those developing company’s proprietary cryopreserved NK and gamma delta T-cell candidates…
Prelude Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Update
– Dose Escalation Portion of Phase 1 Trial of PRT543 Complete; Additional Expansion Cohorts Set…
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2020 Financial Results
Management to host conference call and webcast on March 23rd at 5:00 pm EDT /…